Humacyte, Inc. (HUMA) Financial Analysis & Valuation | Quarter Chart
Humacyte, Inc. (HUMA)
HUMAPrice: $0.68
Fair Value: 🔒
🔒score
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platfo... more
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengi... more
Description
Shares
| Market Cap | $105.91M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Laura E. Niklason |
| IPO Date | 2020-12-01 | CAGR | -0.17% |
| Employees | 218 | Website | www.humacyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
HUMA chart loading...
Fundamentals
Technicals
| Enterprise Value | $166.26M | P/E Ratio | -4.22 |
| Forward P/E | -3.77 | PEG Ratio | — |
| P/S Ratio | 51.97 | P/B Ratio | 34.37 |
| P/CF Ratio | -1.02 | P/FCF Ratio | -1 |
| EPS | $-0.27 | EPS Growth 1Y | -82.54% |
| EPS Growth 3Y | -414.29% | EPS Growth 5Y | -97.42% |
| Revenue Growth 1Y | -71.8% | Gross Margin | -1.34% |
| Operating Margin | -53.06% | Profit Margin | -20.04% |
| ROE | -4.25% | ROA | -0.35% |
| ROCE | -1.1% | Current Ratio | 3.69 |
| Quick Ratio | 2.95 | Cash Ratio | 2.75 |
| Debt/Equity | 20.86 | Interest Coverage | -21.64 |
| Altman Z Score | -8.8 | Piotroski Score | 1 |